Atropine/difenoxin

Fsn0503h (anti-Cathepsin S) is an antagonistic monoclonal antibody targeting cathepsin S. It has a potential to inhibit invasion of tumors, and targeting neovascularization in colorectal carcinoma.

Fsn0503h (anti-Cathepsin S) is an antagonistic monoclonal antibody targeting cathepsin S. It has a potential to inhibit invasion of tumors, and targeting neovascularization in colorectal carcinoma.

Fsn0503h (anti-Cathepsin S) is an antagonistic monoclonal antibody targeting cathepsin S. It has a potential to inhibit invasion of tumors, and targeting neovascularization in colorectal carcinoma.

A structural analog of sphingosine and a novel immune modulator inhibits lymphocyte emigration from lymphoid organs becomes phosphorylated by sphingosine kinase in vivo to act as a potent agonist at S1P1, S1P3, S1P4, and S1P5.

A structural analog of sphingosine and a novel immune modulator inhibits lymphocyte emigration from lymphoid organs becomes phosphorylated by sphingosine kinase in vivo to act as a potent agonist at S1P1, S1P3, S1P4, and S1P5.

A structural analog of sphingosine and a novel immune modulator inhibits lymphocyte emigration from lymphoid organs becomes phosphorylated by sphingosine kinase in vivo to act as a potent agonist at S1P1, S1P3, S1P4, and S1P5.

Haspin-IN-3 (compound 8l) is a potent haspin inhibitor with IC 50 of 14 nM. Haspin-IN-3 has anticancer effectsForm:SolidIC50&amp: Target:IC50: 14 nM (Haspin).

Haspin-IN-3 (compound 8l) is a potent haspin inhibitor with IC 50 of 14 nM. Haspin-IN-3 has anticancer effectsForm:SolidIC50&amp: Target:IC50: 14 nM (Haspin).

Haspin-IN-3 (compound 8l) is a potent haspin inhibitor with IC 50 of 14 nM. Haspin-IN-3 has anticancer effectsForm:SolidIC50&amp: Target:IC50: 14 nM (Haspin).

Haspin-IN-3 (compound 8l) is a potent haspin inhibitor with IC 50 of 14 nM. Haspin-IN-3 has anticancer effectsForm:SolidIC50&amp: Target:IC50: 14 nM (Haspin).

I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonistIn VitroI-191 inhibits cytokine production as well as cytokine-related caspase cleavages via ERK1/2 signaling in HT29 colon cancer cells. MCE has not independently confirmed

I-191 is a potent, selective protease-activated receptor 2 (PAR2) antagonistIn VitroI-191 inhibits cytokine production as well as cytokine-related caspase cleavages via ERK1/2 signaling in HT29 colon cancer cells. MCE has not independently confirmed